

Item 2.02. Results of Operations and Financial Condition.

On May 17, 2017, Immune Design Corp. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2017. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01. Other Events.

On May 17, 2017, the Company also issued a press release reporting new clinical and biomarker data from the Company’s CMB305 and G100 monotherapy studies, which data will be presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) in June.

A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Press Release, dated May 17, 2017.
99.2	Press Release, dated May 17, 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNE DESIGN CORP.

By: /s/ Carlos Paya, M.D., Ph.D.
Carlos Paya, M.D., Ph.D.
President and Chief Executive Officer

Dated: May 17, 2017

EXHIBIT INDEX

Exhibit Number	Description
-------------------	-------------

99.1	Press Release, dated May 17, 2017.
------	------------------------------------

99.2	Press Release, dated May 17, 2017.
------	------------------------------------